Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine

Vaccine

Volumn 31, Issue 50, 2013, Pages 5989-5996

  Rouleau, Isabelle ^a   De Serres, Gaston ^a,b   Drolet, Jean Philippe ^a   Skowronski, Danuta M ^c   Ouakki, Manale ^b   Toth, Eveline ^d   Landry, Monique ^d   Ménard, Suzanne ^e   Gagnon, Rémi ^a  

^a LAVAL UNIVERSITY   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^c BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^d Ministère de la Santé et des Services Sociaux du Québec   (Canada)

^e Institut Universitaire de première ligne en santé et services sociaux   (Canada)

Author keywords

Adverse effects; Anaphylaxis; Epidemiology; Influenza vaccines; Mass vaccination

Indexed keywords

ADRENALIN; AS03 ADJUVANT; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ADULT; ALLERGY; ANAPHYLAXIS; ARTICLE; BRONCHOSPASM; CANADA; CHEST TIGHTNESS; CLINICAL FEATURE; CONJUNCTIVITIS; COUGHING; DRUG CONJUGATION; DRUG SURVEILLANCE PROGRAM; DYSPHAGIA; DYSPNEA; EYE REDNESS; FACE DISORDER; FEMALE; HOARSENESS; HUMAN; INCIDENCE; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; OXYGEN DESATURATION; PRIORITY JOURNAL; PRURITUS; RASH; RISK FACTOR; SORE THROAT; SWELLING; THROAT TIGHTNESS; WHEEZING;

ADVERSE EFFECTS; ANAPHYLAXIS; EPIDEMIOLOGY; INFLUENZA VACCINES; MASS VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA-TOCOPHEROL; ANAPHYLAXIS; CANADA; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INCIDENCE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; POLYSORBATES; QUEBEC; RISK ASSESSMENT; SQUALENE; YOUNG ADULT;

EID: 84887610564     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.033     Document Type: Article

References (36)

1. National Advisory Committee on Immunization Canadian immunization guide 2006, Public Health Agency of Canada, Ottawa. 7th ed.
2. van der Linden P.W., Struyvenberg A., Kraaijenhagen R.J., Hack C.E., van der Zwan J.K. Anaphylactic shock after insect-sting challenge in 138 persons with a previous insect-sting reaction. Ann Intern Med 1993, 118(February (3)):161-168.
3. Lieberman P., Camargo C.A., Bohlke K., Jick H., Miller R.L., Sheikh A., et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol 2006, 97(November (5)):596-602.
4. Ross M.P., Ferguson M., Street D., Klontz K., Schroeder T., Luccioli S. Analysis of food-allergic and anaphylactic events in the National Electronic Injury Surveillance System. J Allerg Clin Immunol 2008, 121(January (1)):166-171.
5. Erlewyn-Lajeunesse M., Dymond S., Slade I., Mansfield H.L., Fish R., Jones O., et al. Diagnostic utility of two case definitions for anaphylaxis: a comparison using a retrospective case notes analysis in the UK. Drug Saf 2010, 33(January (1)):57-64.
6. Rüggeberg J.U., Gold M.S., Bayas J.M., Blum M.D., Bonhoeffer J., Friedlander S., et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25(August (31)):5675-5684.
7. Auger D., Bourdages J., Dubuque J., Hudon N., Markowski F., Toth E. Bilan de la Direction générale de la santé publlique de la vaccination contre la grippe pandémique A(H1N1) du 22 octobre au 18 décembre 2009. Ministère de la Santé et des Services sociaux du Québec. Gouvernement du Québec 2011, Available from: http://publications.msss.gouv.qc.ca/acrobat/f/documentation/2011/11-220-02.pdf.
8. Erlewyn-Lajeunesse M., Bonhoeffer J., Ruggeberg J.U., Heath P.T. Anaphylaxis as an adverse event following immunisation. J Clin Pathol 2007, 60(July (7)):737-739.
9. Bohlke K., Davis R.L., Marcy S.M., Braun M.M., DeStefano F., Black S.B., et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003, 112(October (4)):815-820.
10. Patja A., Davidkin I., Kurki T., Kallio M.J.T., Valle M., Peltola H. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. Pediatr Infect Dis J 2000, 19(12):1127-1134.
11. Groupe Central ESPRI Surveillance des manifestations cliniques inhabituelles survenues après la vaccination contre la grippe A(H1N1) lors de la campagne de masse de l'automne 2009 au Québec 2010, Ministère de la Santé et des Services sociaux du Québec, Québec, QC, 18 aoÛt.
12. Lieberman P. Use of epinephrine in the treatment of anaphylaxis. Curr Opin Allergy Clin Immunol 2003, 3(August (4)):313-318.
13. Lieberman P.L. Anaphylaxis. Middleton's allergy: principles and practice 2008, 1027-1050. Mosby, Philadelphia, PA. 7th ed. N. Adkinson, B. Bochner, W. Busse, S. Holgate, R. Lemanske, F. Simons (Eds.).
14. Chen W., Mempel M., Schober W., Behrendt H., Ring J. Gender difference, sex hormones, and immediate type hypersensitivity reactions. Allergy 2008, 63(November (11)):1418-1427.
15. Spellberg B., Edwards J.E. Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis 2001, 32(January (1)):76-102.
16. Vellozzi C., Broder K.R., Haber P., Guh A., Nguyen M., Cano M., et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010, 28(October (45)):7248-7255.
17. Cano M., Lewis P., Ou A.C., Sharma D., Vellozzi C., Broder K.R. Bell's palsy cases following administration of influenza A (H1N1) 2009 monovalent vaccine reported to the vaccine adverse event reporting system (VAERS). J Vaccines Vaccin 2012, 3(2):1000134.
18. Mahajan D., Roomiani I., Gold M.S., Lawrence G.L., McIntyre P.B., Menzies R.I. Annual report: surveillance of adverse events following immunisation in Australia, 2009. Commun Dis Intell Q Rep 2010, 34(September (3)):259-276.
19. Liang X.F., Li L., Liu D.W., Li K.L., Wu W.D., Zhu B.P., et al. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. New Engl J Med 2011, 364(February (7)):638-647.
20. Health Sciences Authority. Summary on Safety Monitoring of H1N1 Vaccines from 3 November 2009 to 31 July 2010 [On line]. Available from: http://www.hsa.gov.sg/publish/content/hsaportal/en/for_public/influenza_a_-_h1n1/h1n1_vaccines/update_on_safety_monitoring0.html.
21. van Puijenbroek E.P., Broos N., van Grootheest K. Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands. Drug Saf 2010, 33(December (12)):1097-1108.
22. Agenzia Italiana del Farmaco Rapporto sulla sorveglianza postmarketing dei vaccini in Italia 2009-2010: Agenzia Italiana del Farmaco 2010.
23. Ministerio de Sanidad y politica social Informe final sobre seguridad de las vacunas frente a la gripe A H1N1 pandémica en Espana - Resultados del Plan de Farmacovigilancia de las vacunas pandémicas 16 de noviembre de 2009 a 15 de marzo de 2010 2010, 5.
24. ® database on suspected adverse events following pandemic influenza (H1N1) 2009 vaccination in Switzerland: Swiss Agency for Therapeutic Products 2010 July.
25. Paul Ehrlich-Institut Information zu Verdachtsfallberichten von Nebenwirkungen und Impfkowplikationen nach Anwendung der in Deutschland zugelassenen Schweinegrippe (H1N1)-Impfstoffe: Paul Ehrlich-Institut 2010.
26. Lakemedelsverket Medical Product Agency. Final summary of adverse drug reaction reports in Sweden with Pandemrix through October 2009 - mid April 2010; 2010. Available from: http://www.lakemedelsverket.se/upload/eng-mpa-se/Pandemrix%20ADRs%20in%20Sweden%2015%20april%202010.pdf.
27. Medicines and Healthcare products Regulatory Agency Final public summary - UK Suspected Adverse Reaction Analysis/Swine Flu (H1N1) Vaccines - Celvapan and Pandemrix: Medicines and Healthcare products Regulatory Agency (MHRA) 2010.
28. Statens legemiddelverk Norwegian Medicines Agency Bivirkningsrapport 2010: Seksjon for legemiddelovervaking 2010.
29. Madsen S., Andersen S.R., Bergsaker M.A., Buajordet I., Ege M.S., Harg P., et al. Meldte bivirkninger av pandemivaksinen Pandemrix i Norge 2010, 31-35.
30. Agence française de sécurité sanitaire des produits de santé. Suivi de Pharmacovigilance des vaccins grippaux A (H1N1). Bulletin no 17:1-12.
31. Irish Medicines Board Suspected Adverse Reactions to Pandemic (H1N1) 2009 Vaccines occurring in Ireland 2009, 5.
32. Folkenberg M., Callreus T., Svanstrom H., Valentiner-Branth P., Hviid A. Spontaneous reporting of adverse events following immunisation against pandemic influenza in Denmark November 2009-March 2010. Vaccine 2011, 29(February (6)):1180-1184.
33. Tavares F., Delaigle A., Slavin D., Bauchau V., Fries L., Seifert H. Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective. Vaccine 2011, 29(August (37)):6402-6407.
34. Kurz X., Domergue F., Slattery J., Segec A., Szmigiel A., Hidalgo-Simon A. Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance. Vaccine 2011, 29(June (26)):4378-4387.
35. Zhou W., Pool V., Iskander J.K., English-Bullard R., Ball R., Wise R.P., et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. MMWR Surveill Summ 2003, 52(January (1)):1-24.
36. Rumke H.C., Richardus J.H., Rombo L., Pauksens K., Plassmann G., Durand C., et al. Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC Infect Dis 2013, 13:348.